Bavarian Nordic (BAVA)

Currency in DKK
238.8
+0.2(+0.08%)
Closed·
BAVA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
BAVA is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
237.8244.8
52 wk Range
123.3284.7
Key Statistics
Prev. Close
238.6
Open
240.5
Day's Range
237.8-244.8
52 wk Range
123.3-284.7
Volume
347.48K
Average Volume (3m)
348.77K
1-Year Change
-13.73%
Book Value / Share
154.8
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BAVA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
244.0
Upside
+2.18%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Bavarian Nordic News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Bavarian Nordic Company Profile

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Employees
1667
Market
Denmark

Bavarian Nordic Earnings Call Summary for Q2/2025

  • Revenue surged 33% to ~3B Danish kroner; gross margin improved to 55% from 44% YoY
  • Sold Priority Review Voucher for $810M; launched Vincunia vaccine for chikungunya
  • Refined revenue guidance to 6.0-6.6B Danish kroner; EBITDA margin guidance maintained at 26-30%
  • Travel health revenue projected at 2.5-2.75B; public preparedness revenue forecast at 3.1-3.7B
  • CEO highlighted 3.1B kroner in secured contracts; CFO noted increasing market awareness
Last Updated: 22/08/2025, 14:00
Read Full Transcript

Compare BAVA to Peers and Sector

Metrics to compare
BAVA
Peers
Sector
Relationship
P/E Ratio
13.1x−4.6x−0.6x
PEG Ratio
0.13−0.090.00
Price/Book
1.5x2.5x2.6x
Price / LTM Sales
2.9x13.9x3.3x
Upside (Analyst Target)
2.2%190.2%38.0%
Fair Value Upside
Unlock−1.5%4.4%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 244.0
(+2.18% Upside)

Earnings

Latest Release
Aug 22, 2025
EPS / Forecast
2.67 / --
Revenue / Forecast
1.43B / 1.65B
EPS Revisions
Last 90 days

BAVA Income Statement

People Also Watch

363.9
NOVOb
+2.19%
3.4210
SABE
0.00%
1,570.0
GMAB
-0.25%
646.20
ASML
+1.84%
1,622.500
RHMG
+0.87%

FAQ

What Stock Exchange Does Bavarian Nordic Trade On?

Bavarian Nordic is listed and trades on the Copenhagen Stock Exchange stock exchange.

What Is the Stock Symbol for Bavarian Nordic?

The stock symbol for Bavarian Nordic is "BAVA."

What Is the Bavarian Nordic Market Cap?

As of today, Bavarian Nordic market cap is 18.60B.

What Is Bavarian Nordic's Earnings Per Share (TTM)?

The Bavarian Nordic EPS (TTM) is 18.04.

When Is the Next Bavarian Nordic Earnings Date?

Bavarian Nordic will release its next earnings report on 13 Nov 2025.

From a Technical Analysis Perspective, Is BAVA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Bavarian Nordic Stock Split?

Bavarian Nordic has split 5 times.

How Many Employees Does Bavarian Nordic Have?

Bavarian Nordic has 1667 employees.

What is the current trading status of Bavarian Nordic (BAVA)?

As of 24 Aug 2025, Bavarian Nordic (BAVA) is trading at a price of 238.80, with a previous close of 238.60. The stock has fluctuated within a day range of 237.80 to 244.80, while its 52-week range spans from 123.30 to 284.70.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.